Discover
CNTX
Context Therapeutics Inc.
0.61
2 x 0.43
2 x 0.74
bid
ask
+
0.05
9.82%
2 @ 05:50 AM
0.59 -0.02 (3.45%)
| Ytd | -58.62% | |
| 1y | -3.14% |
0.56
day range
0.63
0.55
52 week range
3.62
| Open | 0.57 | Prev Close | 0.55 | Low | 0.56 | High | 0.63 | Mkt Cap | 55.89M |
| Vol | 4.30M | Avg Vol | 1.85M | EPS | -0.42 | P/E | N/A | Forward P/E | -3.38 |
| Beta | 2.25 | Short Ratio | 2.79 | Inst. Own | 76.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 1.87 | 200-d Avg | 1.77 | 1yr Est | 7.70 |
CNTX News
benzinga.com
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lo
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with
benzinga.com
Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispeci
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session